Ligachem Bioscience Receives ADC Platform Technology Transfer Milestone from Ono Pharmaceutical

Ligachem Bioscience announced on January 8 that it is scheduled to receive a development milestone payment related to its ADC (antibody-drug conjugate) platform technology transfer from Ono Pharmaceutical Co., Ltd. of Japan.

This milestone is a follow-up achievement to the ADC platform technology transfer agreement signed in October 2024. At that time, the two companies entered into a joint research and candidate discovery agreement utilizing Ligachem Bioscience's proprietary ADC platform, "Conjugall."

Immediately after signing the agreement, in March of last year, Ligachem Bioscience and Ono Pharmaceutical completed the designation of the first target, achieving the initial milestone. Since then, research and development of the ADC candidate based on this target has progressed smoothly according to the original schedule, leading to the receipt of this additional milestone.

While the specific size and detailed terms of the milestone remain undisclosed in accordance with the contract between the two companies, this achievement is being recognized as evidence that Ligachem Bioscience's platform technology is demonstrating a stable development pace that meets the high standards of global pharmaceutical companies.

Park Sejin, CEO of Ligachem Bioscience, stated, "This milestone payment is more than a one-time profit; it reaffirms the strong trust between us and Ono Pharmaceutical, as well as the outstanding scalability of our ADC platform technology. Receiving this news at the start of the new year is an indicator that Ligachem Bioscience's commitment to 'performance-driven R&D' is being steadily fulfilled. We will continue to enhance shareholder value and solidify our status as a global leader in ADCs through ongoing pipeline advancement and increased technology revenue."

Meanwhile, Ligachem Bioscience is also approaching milestone achievements for several pipeline projects in collaboration with other global partners besides Ono Pharmaceutical. The company expects that the value of its ADC platform technology and development outcomes will accelerate throughout this year.